Roundview Capital LLC United Therapeutics Corp Transaction History

Roundview Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$211.82 - $248.24 $210,760 - $246,998	995 Added 41.88%	3,371 $761,000
Q1 2023 May 09, 2023	BUY	$212.99 - $276.17 $104,365 - $135,323	490 Added 25.98%	2,376 $532,000
Q4 2022 Feb 13, 2023	SELL	$205.95 - $280.43 $452,060 - $615,543	-2,195 Reduced 53.79%	1,886 $524,000
Q2 2022 Aug 11, 2022	BUY	$174.81 - $241.14 $209,772 - $289,368	1,200 Added 41.65%	4,081 $962,000
Q1 2022 May 11, 2022	SELL	$166.16 - $213.96 $121,795 - $156,832	-733 Reduced 20.28%	2,881 $517,000
Q4 2021 Feb 10, 2022	BUY	$184.32 - $216.08 $375,091 - $439,722	2,035 Added 128.88%	3,614 $781,000
Q2 2021 Aug 10, 2021	SELL	$170.47 - $211.93 $232,691 - $289,284	-1,365 Reduced 46.37%	1,579 $283,000
Q1 2021 May 14, 2021	BUY	$153.94 - $174.85 $453,199 - $514,758	2,944 New	2,944 $492,000
Q1 2018 May 14, 2018	SELL	$107.21 - $151.94 $198,338 - $281,089	-1,850 Closed	0 $0
Q3 2017 Nov 13, 2017	SELL	$114.6 - $136.81 $103,140 - $123,129	-900 Reduced 32.73%	1,850 $217,000
Q3 2017 Nov 13, 2017	BUY	$114.6 - $136.81 $315,150 - $376,227	2,750	2,750 $357,000

673

42.2M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Roundview Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Roundview Capital LLC with notifications on news.